NWRD08 administered by electroporation

Phase 2

WUXI (WXI)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

WXIPhase 2

NWRD08 administered by electroporation Phase 2 Est. Readout

NWRD08 administered by electroporation• High-grade Squamous Intraepithelial Lesion (HSIL)150

Q2 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in High-grade Squamous Intraepithelial Lesion (HSIL)

View Full Landscape

Drug Information

Target Indication

High-grade Squamous Intraepithelial Lesion (HSIL)

Clinical Trial

NCT07175662

Last updated: 6/27/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

WXI

WUXI

Healthcare•North America•NASDAQ

Related Pipeline

Guideline-directed medical therapy (GDMT) for heart failurePhase 3

Pulmonary Hypertension

Mesenchymal Stem CellsPhase 3

Knee Osteoarthritis

CU-20101 treatment for Moderate to Severe Glabellar StriaePhase 3

Glabellar Frown Lines

CU-40102 SprayPhase 3

AGA

5 mg BGM0504 injectionPhase 3

Overweight or Obesity

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts